Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations
JCO Oncology Advances · 2025
DOI: 10.1200/oa-24-00032 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2025. Verfasst von Ibrahim Azar und 26 weiteren Autor:innen. Beteiligte Einrichtung: IHA Hematology Oncology, Pontiac, MI. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, necessitating the identification of resistance mechanisms for effective treatment strategies. Previous studies suggest that targeting the aberrant expression of mTOR regulators p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyl transferase (NAMPT) sensitizes pNENs to everolimus. In this study, we queried a large real-world data set of pNENs, characterizing the molecular and immune landscapes, as well as the clinical outcomes associated with aberrant PAK4 and NAMPT expression. METHODS Two-hundred and ninety-four pNEN cases were analyzed using next-generation sequencing and whole-exome/whole-transcriptome sequencing. We stratified patients into clusters on the basis of median cutoff. RESULTS High expression of genes activated in response to mTOR activation was found in NAMPT-high and PAK4-high groups. Enrichment of PI3K/AKT/mTOR and glycolysis pathways was observed in these tumors. Higher mutation rates in multiple endocrine neoplasia type 1, alpha thalassemia/mental retardation syndrome X-linked, TSC2, SETD2, and CCNE1 were observed in high NAMPT and PAK4 clusters. Immune analysis revealed enrichment in inflammatory response pathways, IL2/STAT5 signaling, and immune checkpoint genes. Increased neutrophils, natural killer cells, and macrophages were found in PAK4-high/NAMPT-high tumors. Analysis of real-world patient data revealed that high PAK4 ( P = .0428) or NAMPT ( P = .0002) expression individually correlated with lower overall survival in all neuroendocrine neoplasms (NEN) cohorts, while the combined high expression of both was associated with the worst outcomes ( P = .0002). Similar trends were observed in pancreatic NEN cohorts. CONCLUSION Our study demonstrates that PAK4-high/NAMPT-high pNENs are associated with distinct molecular and immune profiles. Further investigation is warranted to determine if dual PAK4 and NAMPT blockade enhances the efficacy of immunotherapeutics.
Autor:innen und Institutionen
- IHA Hematology Oncology, Pontiac, MI.
- Wayne State University, Detroit, MI.
- Barbara Ann Karmanos Cancer Institute, Detroit, MI.
- Caris Life Sciences, Phoenix, AZ.
- University of California Irvine, Orange, CA.
- Winship Cancer Institute of Emory University, Atlanta, GA.
ORCID-Profile: Ibrahim Azar, Husain Yar Khan, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Nikhil Vojjala, Moh'd M Khushman, Heloisa P Soares, Philip Agop Philip, Bassel El-Rayes, Emil Lou, Alex Patrick Farrell, Matthew James Oberley, Chadi Nabhan, Sanjay Goel, Anthony F Shields, Boris C Pasche
Förderung
- NCI NIH HHS
Zitieren
APA
Azar, I., Khan, H. Y., Bannoura, S. F., Gandhi, N., Uddin, M. H., Nagasaka, M., Gong, J., Nazha, B., Choucair, K., Vojjala, N., Khushman, M. M., Soares, H. P., El-Deiry, W. S., Philip, P. A., El-Rayes, B., Chen, H., Lou, E., Muqbil, I., Farrell, A. P., …, & Azmi, A. S. (2025). Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations. JCO Oncology Advances. https://doi.org/10.1200/oa-24-00032
Vancouver
Azar I, Khan HY, Bannoura SF, Gandhi N, Uddin MH, Nagasaka M, et al. Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations. JCO Oncology Advances. 2025. doi:10.1200/oa-24-00032
BibTeX
@article{Azar2025,
author = {Azar, Ibrahim and Khan, Husain Yar and Bannoura, Sahar F and Gandhi, Nishant and Uddin, Md Hafiz and Nagasaka, Misako and Gong, Jun and Nazha, Bassel and Choucair, Khalil and Vojjala, Nikhil and Khushman, Moh'd M and Soares, Heloisa P and El-Deiry, Wafik S and Philip, Philip Agop and El-Rayes, Bassel and Chen, Herbert and Lou, Emil and Muqbil, Irfana and Farrell, Alex Patrick and Swensen, Jeffrey and Oberley, Matthew James and Nabhan, Chadi and Goel, Sanjay and Shields, Anthony F and Mohammad, Ramzi M and Pasche, Boris C and Azmi, Asfar S},
title = {Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations},
journal = {JCO Oncology Advances},
year = {2025},
doi = {10.1200/oa-24-00032}
}
EUVIMED